secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2023-06-22T23:59:59+00:00
Accession:  0001193125-23-172678
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Taysha regains Nasdaq independence compliance; Manning resigns, Stalfort appointed
--------------------------------------------------------------------------------

- Paul Manning resigned from board effective June 20, 2023 to enable compliance with Nasdaq Rule 5605(b)(1); remains as non-voting observer.
- Sean Stalfort appointed as independent Class I director, chair of Nominating/Governance Committee, and member of Compensation Committee.
- Stalfort granted option for 43,800 shares at closing price, vesting over 36 months; annual retainer $35k plus committee fees.
- Majority of board now independent; company has regained compliance with Nasdaq listing requirements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523172678/0001193125-23-172678-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523172678/d321956d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-172678

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer